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Magnetic resonance spectroscopic imaging
Ultra-short acquisition delayLong echo time (TE) MR spectroscopy (MRS) sequences are sensitive only to metabolites of low molecular
weight. At shorter TE, signiﬁcantly more metabolite signals are detectable, including broad signals of high-
molecular-weight macromolecules (MMs). Although the presence of MM resonances can bias metabolite quan-
tiﬁcation at short TE, proper quantiﬁcation of MMs is important since MMs themselves may serve as potentially
valuable biomarkers for many pathologies.
We have therefore developed an FID-based 2D-MR Spectroscopic Imaging (2D-MRSI) sequence to map MMs in
healthy brain tissue at 7 Twithin a scan time of ~17min and a repetition time of 879ms. This 2D-MRSI technique
provides MMmaps over a whole slice (i.e., including cortical gray matter) at an ultra-short acquisition delay of
1.3 ms, using double inversion for efﬁcient nulling of low-molecular-weight metabolites.
The optimal sequence parameters were estimated using Bloch simulations, phantom testing, and in vivo validation.
The acquired in vivoMM spectra (n=6) included nine distinct MM peaks in the range of ~0.9–3.7 ppm. The mea-
sured average MM spectrum was incorporated into the LCModel basis set and utilized for further quantiﬁcation of
MRSI data sets without metabolite nulling, which were acquired in ﬁve additional volunteers. The quantiﬁcation
results for two basis sets, one including the MMs and one without MM spectrum, were compared.
Due to the high spectral resolution and full signal detection provided by the FID-MRSI sequence, we could suc-
cessfully map ﬁve important brain metabolites. Most quantiﬁed metabolite signal amplitudes were signiﬁcantly
lower since the inclusion of MMs into the basis set corrected the overestimation of metabolite signals. The
precision of ﬁt (i.e., Cramér Rao lower bounds) remained unchanged. Our MMmaps show that the overall MM
contribution was higher in gray matter than in white matter.
In conclusion, the acquired MM spectrum improved the accuracy of metabolite quantiﬁcation and allowed the
acquisition of high spatial resolution maps of ﬁve major brain metabolites and also MMs.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Proton magnetic resonance spectroscopy (1H-MRS) is a versatile
tool to assess metabolite levels in vivo. In the brain, signiﬁcant changes
in metabolite signals have been detected non-invasively by 1H-MRS in
various diseases (Howe and Opstad, 2003; Jessen et al., 2009; Kantarci
et al., 2004). The advent of ultra-high-ﬁeld MR scanners (i.e., ≥7 T) has
led to an increase of spectral resolution and signal-to-noise ratio
(SNR), thus allowing the quantiﬁcation of more metabolites than atDetection of brainmacromolecules
1H MRSI at 7 Tesla (talk #991).
en, Vienna, Austria. Fax: +43 1
W. Bogner).
. This is an open access article underlower static magnetic ﬁeld strengths (B0) (Tkáč et al., 2009), unless spe-
cial editing (Bogner et al., 2014) or 2D-MRS techniques are being used
(Thomas et al., 2001). This offers a more comprehensive neurochemical
proﬁle of pathologic conditions.
With increasing B0, there has been a trend toward MRS sequences
with shorter echo times (TE). The reason for this is two-fold. On the
one hand, the use of short-TE MRS sequences prevents excessive SNR
loss, particularly that caused by faster T2 relaxation at higher B0. On
the other hand, only at high B0 it is possible to differentiate the low
concentrated metabolic (often J-coupled) resonances since the spectral
resolution is signiﬁcantly improved (Tkáč et al., 2001). The lackof spectral
resolution has long prevented the use of ultra-short-TE MRS sequences
on clinical (e.g., 1.5 T) MR scanners, despite their obvious advantages, in-
cluding the full detection of signal with negligible relaxation/J-coupling
losses. J-coupling-related losses alone account for an ~5- to 10-fold loss
in signal integral between TE ~ 0 ms and 30 ms (Xin et al., 2008).the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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sequences (Bogner et al., 2012;Henning et al., 2009) particularly enhance
the detection of J-coupledmetabolites, such as glutamate ormyo-inositol.
In addition to the improved detection of common brain metabolites
with low molecular weight, ultra-short TE/TE* sequences also provide
increased sensitivity for high-molecular-weight macromolecules
(MM) (Behar et al., 1994) that are often neglected during quantiﬁcation.
This MM contribution is more pronounced at ultra-high B0 due to in-
creased spectral dispersion of the MM components. Several broad MM
peaks in the frequency range 0.9–4.0 ppm overlap with metabolite
peaks, thus making the accurate quantiﬁcation of 1H-spectra challenging
(Cudalbu et al., 2009) but, at the same time, offering the opportunity to
study MM changes in various pathologies (Seeger et al., 2003).
The rationales for the study of brainMMs are two-fold. First, the quan-
tiﬁcation of MMs, per se, is of interest. Increased levels of speciﬁc MM
peaks have been reported at 1.5 T in multiple sclerosis (Mader et al.,
2001; Seeger et al., 2003), stroke (Graham et al., 2001; Hwang et al.,
1996; Saunders et al., 1997), and brain tumors (Seeger et al., 2003).
Thus, MMs may serve as potential biomarkers for multiple brain pathol-
ogies. Preliminary studies on regional, gray matter (GM)/white matter
(WM) tissue, and age variations in the MM levels of healthy volunteers
have been reported using single-voxel spectroscopy (SVS) (Hofmann
et al., 2001; Mader et al., 2002; Schaller et al., 2014). Yet non-pathologic
MM distributions in the healthy brain must be accurately assessed
(i.e., using 1H-MRS imaging (1H-MRSI)) before pathologicMMalterations
can be identiﬁed.
Second, for accurate quantiﬁcation ofmetabolites,MMcontributions
must be properly estimated. Otherwise, the quantiﬁed metabolite con-
centrations may be erroneous (Cudalbu et al., 2012). Several methods
that can account for MM signals exist: (a) mathematical estimation of
MMs (Cudalbu et al., 2009), (b) direct acquisition of MM–free spectra
(Knight-Scott, 1999), and (c) the incorporation of MM spectra measured
in the same subject into quantiﬁcation prior knowledge (Schaller et al.,
2014). The mathematical estimation seems sufﬁciently accurate for
lower B0 (Schaller et al., 2013) but has limitations at ultra-high B0
(Cudalbu et al., 2009). Therefore, adequate handling of MM at B0 ≥ 7 T
should be targeted, either by subtracting the MM background of spectra
(b) or by adding MMs to the ﬁtting prior knowledge (c).
The biochemical background ofMMs is not fully understood, butmost
of the peaksmay be assigned to themethyl andmethylene resonances of
the amino acids of cytosolic proteins (Behar and Ogino, 1993). Common
properties of all MM resonances are shorter T1 and T2 relaxation times
compared to other metabolites. In particular, the faster T1 relaxation
allows the selective detection of MMs using inversion recovery (IR)-
based sequences via metabolite signal suppression (Mader et al., 2001).
Traditional single inversion recovery (SIR) techniques work well with
long repetition times (TR), most notably if the B1+ inhomogeneity over
the volume of interest (VOI) is negligible. The situation is more compli-
cated when spatially variable excitation ﬂip angles, combined with
short TR, cause position-dependent saturation behavior. This causes
inversion times (TI) for optimal metabolite suppression to be spatially
dependent, which induces substantial problems with larger VOIs, such
as in 1H-MRSI. Double-inversion recovery (DIR, i.e., adding a second in-
version pulse) provides superior nulling efﬁciency, as itmakes the satura-
tion behavior insensitive to B1+ inhomogeneities (de Graaf et al., 2006).
Several groups have investigated the human MM resonances for
ultra-short TE using SVS. However, these studies were still carried out
with TEs N 10 ms and long TR (Penner and Bartha, 2014; Schaller et al.,
2014; Snoussi et al., 2014). Further shortening of TEs would increase
the SNR, but due to hardware limitations of clinical MR scanners, it is
not feasible for SVS.
Therefore, in the present study, we adapted a free induction decay
(FID)-based 1H-MRSI sequence to measure MM signal distributions in
the human brain via DIR-based nulling of metabolites with ultra-short
TE* at 7 T. The acquired averageMMspectrumwas used as prior knowl-
edge for a more accurate spectral quantiﬁcation.Materials and methods
Sequence design for metabolite nulling
The spectroscopic data were acquired with an FID-based, two-
dimensional (2D)-MRSI sequence (Bogner et al., 2012) preceded by an
additional DIR module. Two IR pulses (i.e., 10th-order WURST pulses)
were implemented prior to the excitation pulse to obtain metabolite-
nulled spectra (Fig. 1). The inversion time TI1 was deﬁned as the time
interval from the center of the ﬁrst inversion pulse to the center of the
second inversion pulse, while the inversion time TI2 was deﬁned as
the time interval from the center of the second inversion pulse to the
center of the excitation pulse. The duration of both pulses was 40 ms
with a 2000 Hz bandwidth. Repetition time (TR) was deﬁned as the
time from the center of the excitation pulse to the center of the ﬁrst
inversion pulse of the next cycle and includes the duration of the
ADC readout. Therefore, the total duration of one repetition was
TRtot = TI1 + TI2 + TR (see Fig. 1). Such deﬁnition of TR and TRtot was
used to keep saturation effects constant in double-inversion recovery
experiment. The pulse power levels were calibrated manually by in-
creasing the RF power until the adiabatic conditions were fulﬁlled. An
optimized four-pulse WET scheme was used for water suppression
and placed in between the inversion pulses (Ogg et al., 1994).
Simulations and experimental validation
Prior to measurements, simulations were performed to predict the
optimal TI1 values based on iteratively solving the Bloch equations for
different MRSI sequence parameter settings (i.e., TR, TI1, TI2). TR and
TI2 were kept as short as possible to reduce the total measurement
time with regards to speciﬁc absorption rate limits.
T1 and T2 relaxation times for these simulations were those from pre-
vious studies (Penner and Bartha, 2014; Xin et al., 2013). The steady-state
behavior of longitudinal and transversalmagnetizationwas simulated for
MMs and ﬁvemajormetabolites,N-acetyl aspartate (NAA), creatine (Cr),
choline (Cho), glutamate (Glu), andmyo-inositol (Ins), over a TR range of
600–1200ms, as well as a TI1 of 300–1000ms, and a TI2 ranging from 10
to 150 ms. The transversal magnetization for SIR and DIR was simulated
to compare both approaches.
To test the simulation results, several phantommeasurements were
performedwith different ﬂip angles, TI1s, and TI2s; obtained spectrawere
quantiﬁed and compared to simulation output. We used a custom-made
spherical phantom with a diameter of 16 cm that was ﬁlled with brain
metabolites (NAA, Cr, Cho, Glu, Lactate) in a phosphate-buffered solution
at physiological pH and concentration. T1 similar to gray matter was
achieved by dilution of gadolinium-containing agent in the solution.
In order to validate the simulation model and to test the behavior of
MMs in vivo, two of the volunteers underwent six MRSI measurements
in one session using different inversion times (TI1= 300, 400, 500, 570,
600, 700 ms) and a ﬁxed TI2 of 21 ms.
Subjects
Data were acquired from twelve volunteers (eight males, four
females; age, 30 ± 4 years) who had no history of any brain disease on
a 7 Twhole-bodyMR scanner (Magnetom, Siemens Healthcare, Erlangen,
Germany). One data set (male) was excluded due to motion artifacts. All
measurements were performed using a 32-channel receive coil array
combined with a volume transmit coil (Nova Medical, Wilmington, MA,
USA). The study was approved by the Institutional Review Board and
written informed consent was obtained from all volunteers.
Data acquisition
Based on previous simulations, the following data were acquired
from all volunteers with optimized suppression of metabolite signals.
WET
RF
G
x
Gy
G
z
Exc.
TI1 TI2 TR
IR1 IR1IR2
Total TR
Fig. 1. Scheme of the double-inversion recovery 1H-MRSI sequence with interleavedWET water suppression. Two 10th-order WURST pulses and the excitation pulse were separated by
the intervals TI1 and TI2. TI1was deﬁned as the interval from the center of theﬁrst inversion pulse to the center of the second inversion pulse. TI2was deﬁned as the interval from the center
of the second inversion pulse to the center of the excitation pulse. TR was deﬁned as the time from the center of the excitation pulse to the center of the ﬁrst inversion pulse of the next
cycle. Thus, a total duration of one repetition was TRtot = TI1 + TI2 + TR.
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prepared, rapid acquisition gradient echo sequence (MP2RAGE)
(Marques et al., 2010) was acquired for localization purposes. Subse-
quently, a B1+-map was acquired with a pre-saturation, turbo-FLASH-
based B1+ mapping sequence (Chung et al., 2010; Klose, 1992) at the
same position as the MRSI slice. The slice was positioned parallel to
the anterior commissure–posterior commissure (AC–PC) line superior
to the lateral ventricles in the centrum semiovale region (Fig. 2). B0
homogeneity was optimized using standard, second-order, ﬁeld map-
based shimming.
The applied in vivo MRSI parameters were as follows: TR, 879 ms;
TE*, 1.3 ms; TI1, 570 ms; TI2, 21 ms; ﬂip angle, 55°; ﬁeld of view (FoV),
180 × 180 mm2; matrix size, 32 × 32; slice thickness, 12 mm; nominal
voxel size, 5.6 × 5.6 × 12 mm3; 2048 complex spectral data points;
acquisition bandwidth, 3000 Hz oversampled by a factor of 2 to
6000 Hz; one average with an elliptically sampled k-space acquired in aA
Fig. 2. (A) Axial, (B) coronal, and (C) sagittal views of the double-inversion recovery MRSI slic
volume used for the MRSI measurement.pseudo-spiral pattern; four dummy scans; WET water suppression with
40 ms pulse duration (four pulses) and an 80 Hz pulse bandwidth (Ogg
et al., 1994); and scan time ~17 min.
Five additional data sets were measured without inversion recovery
(non-DIR) using a two-dimensional, FID-based MRSI sequence
(Bogner et al., 2012). The sequence parameters were identical except
for the following: TR, 600 ms; ﬂip angle, 45°; FoV, 220 × 220 mm2;
matrix size, 64 × 64; nominal voxel size, 3.4 × 3.4 × 12 mm3; and scan
time, ~30 min.
Spectral processing of MM basis set
To obtain a metabolite- and artifact-free MM spectrum from all sub-
jects, the following steps were taken. A custom script written in Matlab
(version R2009a; The MathWorks, Inc., Natick, MA) and Bash (version
4.2.25, Free Software Foundation, Boston, MA) was used for automated,B
C
e (32 × 32 matrix) positioned on a T1-weighted image. The green box indicates the shim
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which were ﬁrst coil-combined and automatically phase corrected
using MUSICAL (Strasser et al., 2013). Only spectra within a brain
mask, which was derived from the high-resolution T1-weighted
image (Smith, 2002), were processed. In order to decrease peripher-
al lipid contamination, the data sets were Hamming ﬁltered. A region
of interest (ROI) that included 10 × 11 voxels in the central part of
the slice was deﬁned. Spectra from this ROI were exported to
jMRUI 3.0 (Naressi et al., 2001), frequency aligned to correct for B0
inhomogeneities, and summed to increase the SNR. The residual
water peak was removed using Hankel-Lanczos Singular Value Decom-
position (HLSVD). Using a TE* of 1.3 ms introduced a small ﬁrst-order
phase error during data acquisition. For visual and practical purposes,
this error was corrected in jMRUI and later reintroduced prior to inclu-
sion into the LCModel basis set. To obtain metabolite-free MM spectra,
the AdvancedMethod for Accurate, Robust, and Efﬁcient Spectral ﬁtting
(AMARES; Vanhamme et al., 1997) was used to remove any remaining
metabolite signals, as described by Craveiro et al. (2014). A single MM
spectrum consisting of a signal from GM and WM was obtained for
every volunteer. As the spectral resolution of the data acquired fromdif-
ferent volunteers was equally good, it was possible to sum the acquired
MMspectra of all volunteers. Thus, an average in vivoMMspectrumwas
obtained.Metabolite quantiﬁcation with the MM basis set
Todetermine the inﬂuence of adding anMMspectrum to themetab-
olite quantiﬁcation, the average in vivoMM spectrum of six volunteers
was included into an LCModel basis set (Fig. 3) consisting of 17 metab-
olite resonances, as simulated in NMR SCOPE (jMRUI 5.0): α-glucose
(Glc), aspartate (Asp), total choline (tCho) [glycerophosphorylcholine
(GPC)+phosphorylcholine (PCh)], total creatine (tCr) [phosphocreatine
(PCr) + Cr], γ-aminobutyric acid (GABA), Glu, glutamine (Gln),0.
GPC
Ins
NAA
PCr
Glu
MM
4.2 3.0 2.0 1.0 0.5 ppm
Fig. 3. LCModel basis set with a fewmajor metabolite resonances displayed together with
the MM spectrum. For LCModel quantiﬁcation, all 17 metabolites were used, as stated in
Section 2.6. Note that the ﬁrst-order phase of the simulated spectra matches the phase
of the measured data.glutathione (GSH), glycine (Gly), lactate (Lac), Ins, NAA, N-acetyl-
aspartyl glutamate (NAAG), scyllo-inositol (Scyllo), and taurine (Tau).
Pulse simulationswere performed using one hard pulse and FID acquisi-
tion consisting of 32 768 time pointswith 0.0333ms readout dwell time.
Total duration in time domain was 1090.9 ms.
To take the ﬁrst-order phase error due to the TE* into account, the
ﬁrst 39 points of all basis set FIDs were removed, which enabled the
spectral ﬁtting of signal intensities even if the phase of the spectrum
was negative (Bogner et al., 2012; Henning et al., 2009). The same
ﬁrst-order error was reintroduced to the previously obtained average
in vivoMM spectrum.
The ﬁve non-DIR MRSI data sets were quantiﬁed twice using
LCModel 6.3 (Provencher, 2001). For the ﬁrst LCModel processing
cycle, the applied basis set did not account for MM, while for the second
LCModel processing cycle, the averaged in vivoMM spectrum was in-
cluded. MM peaks as provided by LCModel were omitted from the
basis sets because they did not possess the ﬁrst-order error. The fre-
quency range considered for the ﬁrst cycle was 1.8–4.2 ppm, whereas
the second cycle was analyzed from 0.5 to 4.2 ppm to ﬁt all major MM
resonances.
Maps that visualized the distribution of MMs and brain metabolites
of all healthy volunteers were displayed using MINC (MINC tools; v2.0;
McConnell Brain Imaging Center, Montreal, Canada). All data with CRLB
values N20% and line widths N22 Hz were excluded from visualization
and further evaluation.
Evaluation
Themetabolite levels and CRLBs obtained from the ﬁrst and the sec-
ond LCModel processing cycle of non-DIR data sets were compared
voxel-wise, using a Student’s paired t-test. The p-values under 0.01
were considered statistically signiﬁcant. GMandWMregionswere com-
pared separately. The mean difference in signal intensities and CRLBs of
NAA, tCho, tCr, Ins, andGluwere obtained by averaging over all voxels in
the GM/WM region for each subject. Subsequently, these values were
averaged over all subjects. Onlymetabolites that could be reliably quan-
tiﬁed over the whole slice and both in GM and WM in all volunteers
were considered for statistical analysis.
Results
Simulations and validations
Our Bloch simulations predicted an optimal nulling of metabolite
signals for an inversion time TI1 of 570 ms (assuming a ﬁxed TI2 of
21ms and TR time of 879ms, both as short as possible). For this sequence
timing, the simulated signals of NAA, Cr (3 ppm), Cho, Ins, and Glu were
below 5% of the full signal (without inversion). The residual signal of Cr
(4 ppm) was 8% due to its faster T1 relaxation. Simulations showed 53%
remainingMMsignal for SIR compared to 50% for theDIRnullingmethod.
Phantommeasurements conﬁrmed the simulated values. The in vivo DIR
experiment performed in two volunteers provided additional support for
the simulation model, in which the time course of individual signals was
observed (Fig. 4). The smallest metabolic residuals were achieved when
the TI1 was set to 570 ms.
Spectral processing of the MM basis set
The summed metabolite-nulled spectra of all six volunteers were
consistent and provided evidence of the high spectral quality over the
whole frequency range from 0.5 to 4.2 ppm without extracerebral
lipid contamination. Small metabolite residuals were observed in all
MM spectra in accordance with simulations. The residuals of NAA
(2.01 ppm), Ins (3.52 ppm), Glu (2.3 ppm), Gln (2.45 ppm), and tCr
(3.98 ppm) were efﬁciently removed from all metabolite-nulled spectra.
The FWHMofMM1 (0.89 ppm) over all six volunteers was 38.1 Hz± 0.1
1.02.03.04.0
ppm
TI1 (ms)
700
600
570
500
400
300
G
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r
Fig. 4. Series of in vivo double-inversion recovery 1H-MR spectra acquired with ﬁxed
TI2 = 21 ms and variable TI1 (from 300 ms to 700 ms) to determine the optimal timing
to null the metabolites. Data were acquired from one volunteer, but each spectrum is
actually a sum of 110 frequency-aligned spectra (i.e., 10 × 11 voxels) from a rectangular
region of interest located in the centrum semiovale region of brain. Since the spectra are
acquiredwith an acquisition delay,ﬁrst-order phase correctionwas applied. The optimum
for minimizing the metabolite signals was found at TI1 of 570 ms.
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allow simple averaging of the MM spectrum obtained from all six volun-
teers (Fig. 5).1.02.03.04.0 ppm
Vol # 1 
Vol # 2 
Vol # 3 
Vol # 4 
Vol # 5 
Vol # 6 
Sum 
MM1
MM4 MM2
MM5
MM3MM6
MM8 MM7MM9
Fig. 5. A set of MM signals acquired from six healthy volunteers and a sum of these
signals. Spectra were ﬁrst-order phase corrected, and all metabolite residuals were
removed using jMRUI 5.0. Nine distinct MM resonances were detected at the following
frequency positions: 0.91 ppm (MM1), 1.21 ppm (MM2), 1.43 ppm (MM3), 1.67 ppm
(MM4), 2.04 ppm (MM5), 2.26 ppm (MM6), 2.99 ppm (MM7), 3.21 ppm (MM8), and
3.77 ppm (MM9).Metabolite quantiﬁcation with the MM basis set
Basis set comparison
When comparing the quantiﬁcation results obtained from ﬁve non-
DIR 2D-MRSI data sets, processed with/without the inclusion of an MM
spectrum into the LCModel basis set, there were two major ﬁndings:
After the inclusion of MM in the basis set, the metabolite signals
were signiﬁcantly smaller (p b 0.001) for most quantiﬁed metabo-
lites (Fig. 6A). The differences are summarized in Table 1.
The ﬁtting precision (i.e., CRLBs provided by the LCModel) remained
unchanged (p b 0.005) (Table 2).
Regional differences
MM differences (i.e., quantiﬁed MM signal from the 0.5 to 4.2 ppm
region) were found between GM and WM, with higher signal in the
GM regions (Figs. 7A and 8).
In addition, we also found regional and GM/WMdifferences in other
metabolites (Figs. 7A, 8, and 9). Representative spectra fromGMandWM
regions are shown (Figs. 7B and C), together with an overall ﬁt and the
ﬁtted MM spectrum. The tCr signal was higher in GM than in WM re-
gions, whereas tCho was higher in the central WM region. Glu exhibited
a lower signal intensity inWM. NAA and GSHwere relatively evenly dis-
tributed throughout the measured brain slice.
Discussion
In our study, we mapped the MM overall signal in the human brain
in vivo using a 2D 1H-MRSI FID-based sequence with an ultra-short TE*
and DIR-basedmetabolite nulling at 7 T. The parameters were optimized
by simulation and validated by a set of in vitro and in vivo tests. The aver-
age MM spectrum of six volunteers was incorporated into the LCModel
basis set to account for spectral MM contributions during metabolic
quantiﬁcation of non-DIR spectra. The use of this improved ﬁtting prior
knowledge allowed the high-resolution mapping of regional differences
in MMs. Our approach removed the overestimation of metabolite sig-
nals that is presentwhen a solely spline baseline is used. Thus, the quan-
tiﬁcation accuracy was improved, whereas the quantiﬁcation precision
(i.e., CRLBs) remained unchanged.
Double-inversion recovery
SIR is usually the method of choice for metabolite nulling. However,
the situation is different at ultra-high ﬁelds and sequences with very
short TR. The use of spatially variable excitation ﬂip angles, combined
with a short TR, leads to spatially dependent saturation effects. These
saturation effects themselves affect the ideal TI for perfect nulling of
metabolite signals. Moreover, not using a 90° excitation leads to signal
loss. DIR improves the nulling efﬁciency, as it is insensitive to B1+ inhomo-
geneities. DIR provides improved suppression of metabolite resonances
(de Graaf et al., 2006) with no signiﬁcant difference in the remaining
MM signal amplitude. However, DIR can introduce stronger T1 weighting
to the MM resonances compared to SIR (de Graaf et al., 2006), which is a
disadvantage for long-TR sequences. Nevertheless, the use ofMM spectra
acquired via DIR might be advantageous when used to quantify short-TR
spectra. In our study, we did not observe any changes in ﬁtting quality
(CRLBs) when themeasuredMM spectrumwas included in the LCModel
basis set.
MM acquisition
In order to increase the SNR of our acquired MM signal, MM spectra
obtained from the central part of the brain were summed after visual in-
spection for spectral quality and after frequency correction. Although a
difference in the MM spectrum between WM and GM was reported, it
has been suggested that a generalMMspectrum that does not distinguish
-30
-20
-10
0 NAA Glu Ins tCr tCho
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Fig. 6. (A) Mean signal intensity difference (mean ± SE) between the ﬁrst and second LCModel processing cycle obtained in the WM and in the GM of ﬁve volunteers. During the ﬁrst
processing cycle, a basis set without MM spectrum was used, whereas in the second cycle, the same basis set plus the average MM spectrum was used for spectral ﬁtting. A signiﬁcant
decrease of metabolic concentrations (*statistical signiﬁcance, p b 0.001) was observed for NAA, Glu, Ins, tCr, and tCho in both the GM and WM regions for cycle two. (B) The position
of the investigated WM (6 × 4 voxels) and GM (8 × 3 voxels) regions of interest are indicated by white rectangular boxes.
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quantiﬁcation in the healthy human brain (Schaller et al., 2014). In
accordance with that observation, we used a summed MM signal that
originated from both WM and GM regions. The variations in the MM
spectrum between volunteers were not considered signiﬁcant (i.e., the
full width at half maximum of the MM resonance at 0.9 ppm (MM1)
was tested between subjects). The line widths observed for the MM1
resonance (~38 Hz) were comparable to those previously observed at
7 T (~43 Hz) (Snoussi et al., 2014). We found modest differences in the
MM2 and MM4 resonances and in the frequency region from 3.5 to
4.2 ppm. These differences could be explained by different contributions
of GM and WM volume covered by the summed voxels and were
neglected as recently proposed (Schaller et al., 2014). The proper deﬁni-
tion of the prior knowledge on frequency, line width, phase, and ampli-
tude in AMARES algorithm ensured that a precise and robust removal
of residual metabolite peaks was achieved, while avoiding the over- or
underestimation of the MM spectrum.
Summing theMM spectrum that was obtained from several voxels in
a speciﬁed ROI led to an improved SNR without degradation of spectral
resolution. Ding et al. (2014) showed that the line widths after summing
several frequency-aligned MRSI voxels over a speciﬁed ROI were signiﬁ-
cantly smaller than the line widths of spectra obtained by SVS from the
same ROI. This indicates that MRSI should be favored over SVS, if larger
ROIs are needed to reliably detect a metabolite. However, the a priori
better SNR of SVS should be considered (Zhang et al., 2012).
Other MM detection approaches
To the best of our knowledge, only two studies at a lower ﬁeld-
strength (i.e., 2.1 T) were published about how the MM signal shouldTable 1
Mean metabolite signal intensity difference between the data set quantiﬁed with and
without MM included in the basis set. A decrease of all major metabolite signals was ob-
served. The mean signal intensity difference was obtained by averaging the mean signal
intensity differences of individual subjects.
Mean signal intensity difference (%) ± SE
WM GM
Metabolite
NAA −15.9 ± 0.8 −24.9 ± 1.5
tCho −10.6 ± 3.4 −8.3 ± 3.1
tCr −7.3 ± 2.1 −4.5 ± 0.7
Glu −12.0 ± 1.1 −14.6 ± 1.7
Ins −12.3 ± 2.7 −12.5 ± 1.9be handled when using MRSI. Hwang et al. (1996) detected MM in
healthy volunteers and patients with subacute stroke, and Graham
et al. (2001) focused solely on stroke patients. Metabolic maps of two
major MM peaks (i.e., 0.9 ppm and 2.05 ppm) from healthy subjects
and of the 1.3 ppm resonance for patients were presented. However,
the echo timewasN20ms, and the longmeasurement time and low res-
olution hampered wider clinical application. Moreover, the signal at
1.3 ppmwas mostly assigned to lipids, and not MMs, as noted in recent
studies (Balchandani and Spielman, 2008). Thus, an actual change in
MM resonances, as deﬁned by Behar et al. (1994) in diseased tissue,
was reported solely in SVS studies (Mader et al., 2002; Seeger et al.,
2003).
To our knowledge,MMs have not yet beenmeasuredwith a TE/TE* as
short as that presented in our study. Human studies targeting MMs with
SVS methods (i.e., STEAM, SPECIAL, or semi-LASER localization) have
used TEs ranging from 38 ms down to 12 ms and substantially longer
TRs of several seconds than those used in our study (Mader et al., 2002;
Penner and Bartha, 2014; Seeger et al., 2001; Schaller et al., 2013). Even
animal studies reached TEs no shorter than 2.8 ms (Craveiro et al.,
2014; Cudalbu et al., 2009).Metabolic maps
The spatial distribution and concentration differences between
GM/WM were overall in good agreement with previous studies
(Baker et al., 2008; Bogner et al., 2012; Degaonkar et al., 2005; Emir
et al., 2012; Henning et al., 2009). Five major metabolites (NAA, tCr,
tCho, Ins, Glu + Gln) together with overall signal of MM fulﬁlled the
quality assurance criteria over the whole slice in all volunteers.Table 2
Cramer Rao lower bounds (CRLB,mean±SD) obtained from LCModel analysis of 1H spec-
tra from theWM region and the GM region in ﬁve volunteers (see Fig. 6B), using the basis
set with andwithoutMM spectrum (MMS) included. Fivemajormetaboliteswere chosen
for the analysis.
CRLB (%) ± SD
WM GM
Metabolite With MMS Without MMS With MMS Without MMS
NAA 3.7 ± 0.3 3.4 ± 0.3 3.4 ± 0.3 3.4 ± 0.3
tCho 3.9 ± 0.4 5.1 ± 1.1 3.9 ± 0.1 4.5 ± 0.6
tCr 3.0 ± 0.3 3.1 ± 0.1 3.6 ± 0.4 3.9 ± 0.1
Glu 3.9 ± 0.4 3.5 ± 0.5 7.8 ± 1.1 7.6 ± 0.4
Ins 4.9 ± 0.3 4.6 ± 0.5 6.3 ± 1.3 6.1 ± 1.1
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Fig. 7. (A)Metabolic maps of glutamate (Glu), total creatine (tCr), N-acetyl aspartyl glutamate (NAAG), andmacromolecules (MM) in native 64 × 64 resolution showing the signal inten-
sity distribution over the whole brain slice. A characteristic feature of all fourmetabolic maps is the difference between the GM andWM signal intensity, particularly Glu, and MM signals
are decreased in theWM,whereas NAAG is increased in themesialWM. tCr shows increased signal intensity in GM. 1H-MRSI spectra (black), ﬁt (red), ﬁttedMMspectrum (dotted green),
and ﬁtting residuum (top) of (B) a GMvoxel and (C) aWMvoxel. Arrows indicate the increased signal of tCr andGlu in the GMand increased signal of NAAG in theWM. Overall, the lower
MM spectrum in the WM voxel is also apparent.
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GM,whereas in cortical GM the SNRwas insufﬁcient (see Fig. 7A). A sig-
nal of GSH was observed with CRLB values below 20% in one volunteer
(Fig. 8). NAA was fairly uniformly distributed over the whole slice with
a slightly higher signal in the occipital GM. In contrast, the tCho signal
showed greater regional differences, with lower levels in the GM, ex-
cept the midline frontal GM, where the signal intensity reached the
values of WM, which is in accordance with published papers (Baker
et al., 2008; Degaonkar et al., 2005; Emir et al., 2012). tCr was more
abundant in GM than in WM. A higher NAAG signal in mesial WM
was evident (Pouwels and Frahm, 1998). Glx (i.e., Glu + Gln) levels in
GM were higher than the levels in WM since Glu and Gln are found in
close proximity to neuronal synapses (Baker et al., 2008; Marsman
et al., 2013). In accordancewith previous SVS studies, we found a higher
overall MM signal in GM (especially medial GM) than in WM (Schaller
et al., 2014).
MM—a potential biomarker
The proper handling of the MM signal is mandatory, not only to
achieve improved neurochemical proﬁling but also because of the ad-
vent of fast short-TR and short-TE/TE* MRSI sequences (Boer et al.,
2011; Bogner et al., 2012; Henning et al., 2009). Such sequences are par-
ticularly sensitive to high-molecular-weight resonances, such as MMs,
which can bias accurate quantiﬁcation. Boer et al. did not incorporate
any MM estimation into their MRSI quantiﬁcation routine (Boer et al.,
2012). Henning et al. included a simulated MM baseline, but mathemat-
ical models of the MM baseline, such as a spline baseline, were found to
be insufﬁcient at ultra-high ﬁelds (Cudalbu et al., 2009; Pfeuffer et al.,1999). The spline baseline failed to adequately model the MM back-
ground at B0 ≥7 T,whichwas reﬂected in signiﬁcant quantiﬁcation differ-
ences (Cudalbu et al., 2009; Schaller et al., 2014). This is in agreement
with our observations. Yet the spline baseline is the default baseline
model in the LCModel. Another alternative is to use individual MM reso-
nances present in LCModel by default. However, the introduction of ﬁrst-
order error is not possible, disqualifying this approach fromapplication in
pulse-acquire sequences with acquisition delay.
Therefore, to improve the metabolite quantiﬁcation, the measured
MM contribution should be included in the prior knowledge. This is be-
coming even more important at ultra-high ﬁeld and short/ultra-short
TE. Otherwise, an overestimation of metabolite signals occurs. Preferably,
similar sequence parameters (i.e., TR, TE*, and a localization technique)
should be used to acquire MM spectrum. However, the hardware and
software restrictions sometimes do not allow achieving the same settings
for SVS and MRSI. Hence, adapting our MRSI sequence to measure
metabolite-nulled spectra was the only way to achieve these settings
for such a short TE*.
One of the advantages of MRSI techniques is the possibility to create
metabolic maps that reveal even subtle local changes of metabolite
levels throughout the brain volume.
In our study, an additional map for the distribution of the total MM
amplitude was obtained along with other metabolic maps. This enables
the exploration of any regional or tissue differences for eachmetabolite,
as well as for the MMs. This might be of clinical relevance for brain dis-
eases, which manifest as a diffuse metabolic change over a wider tissue
region rather than a focal change. To date, several studies have shown
altered total MM signal or individual MM peaks in diseased brain
(Graham et al., 2001; Kaiser et al., 2005; Mader et al., 2001; Opstad
Glx GSHT1
30
0
5
0
MMIns tCr
0
15
0
tCho
4
0
NAA
13 3.2
0
24
0
Fig. 8.T1-weigthed image andmetabolicmaps of Glx (i.e., Glu+Gln), GSH, tCho, Ins,MM, tCr, andNAA resampled from64×64 to 128×128 resolution illustrate thehigh spatial resolution
of our metabolic maps.
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only a small region that was restricted to a predeﬁned VOI. Due
to lower ﬁeld-strength and longer TEs, the SNR loss impededGlx/NAAT1
tCho/tCtCho/NAA
0.5
0
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The 2D/3D-MRSI approaches that cover large parts of the brain
typically acquire data of variable spectral quality, ranging from
good-quality spectra to those with either low signal intensities in re-
gions of signiﬁcant CSF contribution or broadened line shapes and
large lipid contamination (Maudsley et al., 2006). The demands on sig-
nal analysis are higher compared to SVS. Thus, robust spectral ﬁtting
routines and quality control should be part of the processing pipeline.
Therefore, our exclusion criteria were set for CRLB and FWHM to
avoid low-quality data from analysis. In addition, all data were proc-
essed using a user-independent, automated post-processing routine,
which facilitated optimization of processing time and minimized user-
induced systematic error.
Limitations
Since there is strong evidence that the different MM resonances are
altered non-uniformly in the diseased brain, healthy MM spectrum
might not be adequate to fully describe the MM contribution in spectra
obtained frompathologically changed brain tissue (Craveiro et al., 2014;
Graham et al., 2001; Mader et al., 2002). Possibly elevated lipid signals
that are, for instance, visible in tumors or attributable to demyelination
should be also considered for good quantiﬁcation (Howe et al., 2003;
Mlynárik et al., 2012). A possible solution would be the parameteriza-
tion of the measured MM spectrum by splitting the full MM spectrum
into individual components (Seeger et al., 2003).
Despite the only minor MM tissue (WM/GM) differences that we
observed, the inclusion of separate WM and GM MM contribution
may further increase the robustness of quantiﬁcation.
Conclusion
The use of our FID-based DIR 1H-MRSI sequence enabled the detec-
tion of macromolecular (i.e., metabolite-nulled) spectra in healthy
human brainswith a short TR and an ultra-short TE* of 1.3ms at 7 T. Im-
provedmetabolite quantiﬁcationwas achieved by including the average
MM spectrum in the LCModel prior knowledge. This provided not
only a more accurate quantiﬁcation and high-resolution mapping
of common brain metabolites at 7 T but also additional maps of
MM distributions over the whole slice. This could be of substantial
value for future studies on the pathophysiology of major neurological
and psychiatric diseases.
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Appendix A
The combination of equations for free precession (Eq. (A.1)) and for
rotation of magnetization (Eq. (A.2)) based on Bloch equations were
used, considering the parameters for double inversion.
M t; T1; T2; θð Þ ¼ A M0 þ B ðA:1Þ
Rxy φð Þ ¼
cos φð Þ 0 sin φð Þ
0 1 0
− sin φð Þ 0 cos φð Þ
2
4
3
5 ðA:2Þ
whereM is the magnetization at time t, t is the time interval during
which the signal decays,M0 is the initial magnetization (i.e., t=0 s), T1
and T2 are longitudinal and transversal relaxation rates (all in seconds),θ is the angular velocity of precession, and φ is the ﬂip angle in degrees.
A and B are deﬁned as follows (Eq. (A.3)):
A ¼
e
−t
T2 0 0
0 e
−t
T2 0
0 0 e
−t
T1
2
4
3
5 
cos θð Þ − sin θð Þ 0
sin θð Þ cos θð Þ 0
0 0 1
2
4
3
5 B ¼
0
0
1−e
−t
T1
2
4
3
5
ðA:3Þ
These equations were implemented in MATLAB (version R2009a;
The MathWorks, Inc., Natick, MA) and solved iteratively to simulate
steady-state behavior. The simulations assumed relaxation times for
brain metabolites at 7 T, as reported previously for T1 (Xin et al.,
2013) and for T2 (Penner and Bartha, 2014).
Appendix B. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2015.07.042.
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